Canada Life’s Alterity Therapeutics ATHE Stock Holding History

Canada Life’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-33	Closed	-$2K	–	2447
2015 Q2	$2K	Buy	+33	New	+$2.48K	﹤0.01%	2621

Other funds holding ATHE

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CAM

Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NCCM

Nine Chapters Capital Management Short Hills, New Jersey $45.4M AUM 14.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Canada Life's ATHE Position: Q3 2015 in Review

Canada Life sold out of Alterity Therapeutics (ATHE) in Q3 2015, closing a stake of 33 shares — an estimated $2K sold.

Canada Life first reported a position in ATHE in Q2 2015 and held it in 1 quarter. The position peaked at $2K in Q2 2015. 20 funds tracked by Wall St. Rank hold ATHE as of Q3 2015.

Canada Life reported no remaining Alterity Therapeutics position as of Q3 2015 after selling out during the quarter.
Canada Life sold 33 Alterity Therapeutics shares in Q3 2015, an estimated $2K.
Canada Life first reported a position in Alterity Therapeutics in Q2 2015 and held it in 1 quarter.
Canada Life's Alterity Therapeutics position peaked at $2K in Q2 2015.
20 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2015.

Based on Canada Life's 13F filing for Q3 2015, filed 10 Nov 2015.